• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Episode 15 - Controlling Drug Prices and Working at the Population Level

Video

As the panelists suggest methods to help control the costs of agents for the treatment of multiple sclerosis (MS) and improve patient care, Gary M. Owens, MD, explains that the US needs to aggressively review a drug’s cost versus its value and make products that do not provide outcomes sufficient to their costs more difficult for clinicians to access and treat patients with.

Dr Owens explains that because clinicians treat their MS patients at a population level, clinical guidelines are a necessity.

Leslie Fish, PharmD, agrees and believes that it is important that healthcare professionals receive clinical data about treatment effectiveness for certain patient populations.

Patricia K. Coyle, MD, suggests that improvements in MS disease activity biomarkers can also help clinicians make more educated decisions about treatment.


Related Videos
dr carol regueiro
dr carol regueiro
Screenshot of Adam Colborn, JD during an interview
dr carol regueiro
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.